<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810730</url>
  </required_header>
  <id_info>
    <org_study_id>0502198069</org_study_id>
    <nct_id>NCT02810730</nct_id>
  </id_info>
  <brief_title>Prevalence of Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma</brief_title>
  <acronym>PAPAFA</acronym>
  <official_title>Prevalence, With Medical Imaging, of the Parenchymatous and/or Ductal Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Saint Joseph Saint Luc de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Saint Joseph Saint Luc de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic adenocarcinoma is the 4th leading cause of cancer in the USA. Its incidence is
      increasing both in France and in Europe, whereas all the other cancers are decreasing in
      Europe. Moreover, its seriousness is still high, with a mortality rate higher than the
      average incidence. The aim of PAPAFA study is to assess the prevalence of the pancreatic
      anomalies which can be revealed thanks to imaging, for patients having a 1st degree
      pancreatic adenocarcinoma familial history. This could allow detection of lesions which are
      less than 10 mm long, and improve the dark prognostic of this pathology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients for whom the MRI and/or the echo endoscopy has shown a parenchymatous or ductal pancreatic anomaly</measure>
    <time_frame>six months after the last inclusion</time_frame>
    <description>For every patients who will have a pancreatic MRI detecting an anomaly, the echo endoscopy will be done. A cytology of the lesion from the echo endoscopy will be done for the solid lesions and for the indetermined cystic lesions (that is to say, the lesions which don't meet the literature set criteria for serous kyst or intraductal papillary and mucinous tumor of the pancreas) ; which is usually done in health care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients for whom the MRI has brought to light a parenchymatous and/or ductal pancreatic anomaly</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients for whom the echo endoscopy has brought to light a parenchymatous and/or ductal pancreatic anomaly</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height of the lesions</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the data from the MRI and those from the echo endoscopy</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localisation of the lesions</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lesions</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspect of the lesion (solid and/or liquid)</measure>
    <time_frame>six months after the last inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Prevalence of Pancreas Adenocarcinomas</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pancreatic MRI in the 6 months following the first consultation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pancreatic MRI</intervention_name>
    <description>Pancreatic MRI in the 6 months following the first consultation</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a 1st degree familial history of pancreas adenocarcinoma

          -  patients older than 40

          -  patients whose life expectancy is &gt; 3 months

          -  inform and consent form signed

          -  patient insured under the French social security system

        Exclusion Criteria:

          -  contraindication to the MRI (pace-maker, implanted metallic material, medical history
             of allergy to the contrast agent, end-stage renal failure, pregnancy, claustrophobia)

          -  contraindication to anesthesia to do the echo endoscopy

          -  1st degree family history of 2 pancreas adenocarinomas

          -  medical history of allergy to benzylic alcool

          -  contraindication to dimeglumine gadobenate

          -  pregnant or breastfeeding woman, according to the questioning

          -  subjets who don't have the legal capacity to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-marie Marion Audibert</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Convert</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infirmerie Protestante</name>
      <address>
        <city>Caluire et Cuire</city>
        <zip>69300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Val d'Ouest</name>
      <address>
        <city>Ecully</city>
        <zip>69130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste des Eaux Claires</name>
      <address>
        <city>Grenoble</city>
        <zip>38028</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre des maladies du foie et de l'appareil digestif</name>
      <address>
        <city>Irigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Joseph Saint Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Villefranche</name>
      <address>
        <city>Villefranche sur Saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Portes du Sud</name>
      <address>
        <city>Vénissieux</city>
        <zip>69694</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas</keyword>
  <keyword>adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

